Mnk1 or Mnk2 inhibitors

US8071607B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Thomas Coulter · Wantage, GB
• Steven John Taylor · Winchester, US
• Stephen Murfin · Biggenden, AU
• Valery Thammalaksa · Paris, FR
• Babette Aicher · Frankfurt am Main, DE
• Stefan Jaekel · Oettingen, DE
• Tanja Reuter · Darmstadt, DE

Key dates

• Filing date: Dec 22, 2005
• Grant date: Dec 6, 2011
• Expiry date: Jun 4, 2027

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P3/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to the use of pyrazolopyrimidine compounds for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.